SCHEMBL7081379

SCHEMBL7081379

C/C(=C\I)c1cc(C(C)(C)C)cc2c1CCC2(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 14/20 0.59
RXRG P48443 8/20 0.49
RXRB P28702 7/20 0.44
RARG P13631 8/20 0.32
RARA P10276 7/20 0.32
RARB P10826 6/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
CYP26A1 O43174 1/20 0.32
GMNN O75496 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
NFKB1 P19838 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081382 1.00 RXRA (0.59) RXRARXRGRXRBRARGRARA
SCHEMBL29374183 0.87 RXRA (0.63) RXRARXRGRXRBRARGRARA
SCHEMBL112943 0.87 RXRA (0.63) RXRARXRGRXRBRARGRARA
SCHEMBL3633427 0.82 RXRA (0.65) RXRARXRGRXRBRARGRARA
SCHEMBL7085844 0.81 RXRA (0.60) RXRARXRGRXRB
SCHEMBL7084251 0.81 RXRA (0.72) RXRARXRGRXRBRARGRARA
SCHEMBL7084088 0.79 RXRA (0.62) RXRARXRGRXRBRARGRARA
SCHEMBL13807401 0.78 RXRA (0.57) RXRARXRGRXRB
SCHEMBL7085816 0.76 RXRA (0.58) RXRARXRGRXRB
Acetic Acid SCHEMBL8421363 0.75 RXRA (0.54) RXRARXRGRXRBRARGRARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191145-A1 Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-09 US disclosed
US-6534545-B1 Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-03-18 US disclosed
US-6180674-B1 THERAPY FOR SKIN DISORDERS GALDERMA RESEARCH & DEVELOPMENT (FR) 2001-01-30 US disclosed
EP-0905118-A1 Unsaturated 6-tert-butyl-1,1-dimethylindane derivates substituted in the 4-position and their use in human and veterinary medicine as well as in cosmetics Galderma Research & Development, S.N.C. (FR) 1999-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191145-A1 Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and in cosmetics REL, DERL1, TLR7 RXRA 30/4885RXRG 77/4885RXRB 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.